Long-Acting Injectable Therapy, Stacked Against Her Own History
A decade of perfect suppression argues for trusting her with a simpler regimen. A resistance test from the very beginning of that decade argues the opposite, and neither fact cancels the other out.
M.A., a 46-year-old woman, has managed the kitchen at a busy diner for eleven years, work that keeps her on her feet ten hours a day and, by her own description, left her with little patience left over in her early twenties for a daily pill she had to remember on top of two jobs and a newborn. She was diagnosed with HIV at 24 and started on efavirenz, tenofovir disoproxil fumarate, and emtricitabine, but a genuinely difficult two-year stretch — job instability, a move between three apartments, an infant to care for largely on her own — left her adherence inconsistent, and a viral load check at 27 showed treatment failure. Resistance testing at the time identified the Y181C mutation, an NNRTI-class resistance-associated mutation that specifically reduces susceptibility to rilpivirine as well as the efavirenz she was already failing. She was switched to a boosted-protease-inhibitor-based regimen afterward and has been virologically suppressed, without a single missed refill by her own report, for the past ten years.
Her current BMI is 34, and she has come in specifically to ask about switching to long-acting injectable cabotegravir/rilpivirine, having seen an advertisement for it and liking the idea of trading daily pills for an injection every two months. FLAIR and ATLAS, the trials that established this regimen's noninferiority to daily oral therapy, enrolled patients without her specific combination of history. The pooled post-hoc analysis across FLAIR, ATLAS, and ATLAS-2M identified three factors independently associated with confirmed virologic failure on this regimen — archived NNRTI resistance mutations affecting rilpivirine, a BMI of 30 or higher, and certain HIV-1 subtypes — and found the risk rose substantially when two or more were present together. She meets two of the three, not as an edge case but concretely: the archived Y181C from her twenties, and a BMI of 34 against the pooled analysis's own cut point of 30.
HIV clinic, switch-of-therapy visit
Ten years of unbroken suppression is real, hard-won evidence about who she is as a patient now, not who she was at twenty-seven managing an infant and two jobs. She's motivated, she's asking for this herself, and adherence to the regimen she's on has been flawless. It's also worth naming that the boosted protease inhibitor she's been on for a decade isn't a free ride — ritonavir-boosted regimens carry a well-documented dyslipidemia signal, and her lipid panel hasn't been part of this conversation the way her adherence has. A switch isn't only about convenience; it's a real chance to get her off a drug class with a known metabolic cost. I'd support it.
I don't doubt her adherence, and I'm not questioning her motivation.
But the ATLAS-2M pooled analysis specifically found that stacked risk factors predict virologic failure independent of adherence — Y181C reduces rilpivirine susceptibility directly, at the drug-target level, regardless of how reliably she takes it, and a BMI of 34 affects the pharmacokinetics of the depot injection itself, not just her behavior. Two of the three named risk factors, together, is exactly the combination that analysis flagged as substantially higher-risk. This isn't a judgment about her; it's about what her own numbers say. And her CD4 of 640 doesn't change that calculus at all — this is a resistance and pharmacokinetic question, not an immunologic one, and a decade of immune reconstitution has no bearing on whether Y181C still compromises rilpivirine.
Both of you are reasoning from a genotype drawn ten years ago. Resistance mutations can persist in the latent reservoir, but they can also be joined by others, or occasionally become a smaller fraction of the archived quasispecies over time. A proviral DNA genotype today would tell us what's actually still there, rather than deciding her candidacy off a record from a very different chapter of her treatment. I'd get that test before either approving or declining the switch.
Agreed: proviral DNA genotyping ordered before any switch decision, with her current regimen continued unchanged in the meantime. If Y181C and any other rilpivirine-relevant mutations are no longer detectable, the primary care physician's case for proceeding gets meaningfully stronger; if they persist, the infectious disease physician's caution holds. That result, not today's discussion, was left as the actual deciding factor.